This week in Other Barks & Bites: the The Federal Circuit denies rehearing in Teva’s case with GlaxoSmithKline’s regarding Teva’s induced infringement of a GSK patent directed to a method of treating Congestive Heart Failure; the Eleventh Circuit affirms that press release statements regarding patent licensing and other business activities by Revolutionary Concepts included false statements violating federal securities law; the World Intellectual Property Organization reports that nearly 55% of international patent application filings during 2021 were submitted by Asian entities; Judge Newman authors a dissent arguing flaws in a Federal Circuit panel majority’s decision to affirm the invalidity of patents covering the opioid overdose treatment NARCAN; Disney’s quarterly earnings show strong results in both streaming subscribers as well as theme park attendance; White House OSTP Director Eric Lander resigns following an investigation into bullying allegations; and a federal indictment surrounding the theft of walkie talkie trade secrets from Motorola Solutions was unsealed in Northern Illinois federal district court.
Patent
- Enablement
- Fee Shifting
- Litigation
- SCOTUS Sustains Blow to Patent Prosecution Practice in Denying Juno v. Kite Rehearing
- Opinion: Restoring The Road Less Traveled – American Invention at a Crossroad
- An Alternative to Claim Mirroring in Initial Patent Application Filing
- Bristol Myers Says AstraZeneca’s Imjudo Infringes Yervoy Patent
- New Federal Law and FTC Rule Will Imperil Trade Secret Protection
Recent Posts
- SCOTUS Sustains Blow to Patent Prosecution Practice in Denying Juno v. Kite Rehearing
- Opinion: Restoring The Road Less Traveled – American Invention at a Crossroad
- An Alternative to Claim Mirroring in Initial Patent Application Filing
- Bristol Myers Says AstraZeneca’s Imjudo Infringes Yervoy Patent
- New Federal Law and FTC Rule Will Imperil Trade Secret Protection